← Back to Search

PD-L1 Inhibitor

Durvalumab for Lung Cancer (ATLANTIC Trial)

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged at least 18 years
Patient's tumour sample must be PD-L1 positive (≥25% of tumour cells with membrane staining (Cohort 1 and 2) or PD-L1 positive with ≥90% of tumour cells with membrane staining (Cohort 3)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of first treatment until final dco (up to approximately 3 years 8 months)
Awards & highlights

ATLANTIC Trial Summary

This trial will study the effects of the drug durvalumab in patients with non small cell lung cancer that has spread to other parts of the body. The trial will assess how well the drug works, as well as its safety and tolerability.

Who is the study for?
This trial is for adults over 18 with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have already tried a platinum-based chemotherapy and one other treatment without success. They should be relatively healthy (WHO Performance Status of 0 or 1), expected to live more than 12 weeks, and their tumors must show certain levels of PD-L1 protein.Check my eligibility
What is being tested?
The study tests the effects of MEDI4736 (Durvalumab), focusing on how well it works, its safety, and how tolerable it is for patients with NSCLC that's either locally advanced or has spread to other parts of the body.See study design
What are the potential side effects?
Possible side effects include immune system reactions that can affect organs, infusion-related reactions similar to allergic responses, fatigue, digestive issues like diarrhea or constipation, skin problems like rash or itching, and potential increased risk of infections.

ATLANTIC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My tumor is PD-L1 positive with specific levels of cell staining.
Select...
My lung cancer is at an advanced stage (IIIB or IV).
Select...
I am fully active or able to carry out light work.
Select...
My NSCLC has worsened after platinum-based chemo and another treatment.

ATLANTIC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of first treatment until final dco (up to approximately 3 years 8 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of first treatment until final dco (up to approximately 3 years 8 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate (ORR)
Secondary outcome measures
Duration of Response (DoR)
Overall Survival (OS)
Time to Response (TTR)

Side effects data

From 2023 Phase 3 trial • 713 Patients • NCT02125461
36%
Cough
24%
Fatigue
22%
Dyspnoea
18%
Diarrhoea
17%
Arthralgia
17%
Radiation pneumonitis
15%
Pyrexia
15%
Decreased appetite
14%
Nausea
13%
Pruritus
13%
Rash
12%
Upper respiratory tract infection
12%
Constipation
11%
Asthenia
11%
Hypothyroidism
11%
Headache
11%
Back pain
10%
Pneumonia
10%
Productive cough
9%
Nasopharyngitis
9%
Insomnia
9%
Pneumonitis
8%
Musculoskeletal pain
8%
Vomiting
8%
Oedema peripheral
8%
Myalgia
8%
Dry skin
7%
Hyperthyroidism
7%
Anaemia
7%
Bronchitis
7%
Dizziness
7%
Non-cardiac chest pain
7%
Pain in extremity
6%
Urinary tract infection
5%
Hypokalaemia
5%
Paraesthesia
5%
Hypertension
5%
Musculoskeletal chest pain
1%
Lung infection
1%
Atrial fibrillation
1%
Myocardial infarction
1%
Cardiac failure congestive
1%
Sepsis
1%
Herpes zoster
1%
Chronic obstructive pulmonary disease
1%
Acute kidney injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
Durvalumab (MEDI4736)
Placebo

ATLANTIC Trial Design

1Treatment groups
Experimental Treatment
Group I: MEDI4736Experimental Treatment1 Intervention
see below
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEDI4736
2016
Completed Phase 3
~5560

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,240 Previous Clinical Trials
288,521,194 Total Patients Enrolled
Phillip Dennis, MD, PhDStudy DirectorAstraZeneca

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What risks have been associated with MEDI4736?

"MEDI4736 is reasonably safe, having earned a score of 2. This reflects the fact that there have been several trials conducted to test its safety but none studying its efficacy yet."

Answered by AI

Can participants younger than two decades old partake in this research endeavor?

"Potential participants must meet the eligibility requirements, which stipulate that they must be between 18 and 130 years of age."

Answered by AI

To what medical conditions is MEDI4736 typically prescribed?

"MEDI4736 can be used to treat those with unresectable stage III non-small cell lung cancer, untreated metastatic ureteral carcinoma and any prior exposure."

Answered by AI

To what extent is the patient population engaged in this clinical trial?

"This clinical study has ceased recruiting patients, with its last edit on October 17th 2022. If you are seeking alternatives for participation, there are 2045 trials actively enrolling people suffering from lung cancer and 333 studies hoping to recruit participants into the MEDI4736 trial."

Answered by AI

Could I be considered a valid participant for this investigation?

"This trial is recruiting 446 participants aged 18 and higher, who have been diagnosed with lung cancer. In order to be eligible for the trial, these patients must have had a previous platinum-based chemotherapy treatment as well as another additional regimen for their NSCLC, possess an estimated life expectancy of more than 12 weeks, and display a World Health Organisation (WHO) Performance Status score of 0 or 1."

Answered by AI

Is this research recruiting new test subjects?

"The records on clinicaltrials.gov indicate that this research initiative is not recruiting participants right now, despite first being posted in February of 2014 and last edited October 17th 2022. Although the trial has concluded its recruitment phase, there are 2378 other studies actively taking candidates at present."

Answered by AI

Are there any additional experiments that have been completed using MEDI4736?

"Currently, there are 333 clinical studies investigating MEDI4736 with 52 of these trials being in their final phase. The majority of the research taking place is located in Cordoba, Texas though 12952 sites across the world are running tests on this drug."

Answered by AI

Are there multiple locations offering this experiment within the US?

"Currently, 32 sites are taking on new participants for this trial. These locations range from Middleton to Port Saint Lucie and New Haven. To decrease the burden of travel, those enrolled should select a site near them if possible."

Answered by AI
Recent research and studies
~40 spots leftby Mar 2025